Arteaus Therapeutics is a US biotech company developing novel therapies for migraine prevention.

Arteaus was formed in 2011 with an $18 million investment from Atlas Venture and OrbiMed, upon acquiring the rights to develop Eli Lilly's calcitonin gene-related peptide (CGRP) antibody.

In June 2012, Arteaus began clinical trials of LY2951742, an antibody to calcitonin gene-related peptide (CGRP), as a potential treatment for the prevention of recurrent migraine headaches.